Actinium Pharmaceuticals Inc
The ATNM stock trades on Nyse Mkt Llc
Company Description
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs not addressed by traditional cancer therapies. Actinium's current clinical pipeline is led by ARCs or Antibody Radiation-Conjugates that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. Actinium's targeted conditioning ARCs seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.
Technology
Actinium's AWE technology platform is used to produce ARCs or Antibody Radiation Conjugates, a highly potent and selective form of targeted radiotherapy. ARCs enable the precision targeting of the proven therapeutic power of radiation to tumors and its synergistic potential with other therapeutic modalities that cannot be matched by traditional external beam radiation, cytotoxic chemotherapy or biologic therapies. AWE enabled ARCs exploit the use of highly selective targeted biological agents such as monoclonal antibodies that can seek out and bind cancer antigens found on the tumor cell surface to deliver potent radioisotopes that are capable of producing double strand DNA breaks for which there is no known resistance or repair mechanisms.
Drug Pipeline
Source: Actinium Pharmaceuticals Inc - 20221106
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
AWE Technology Platform
Multiple Myeloma
Preclinical
Solid Tumors
Preclinical
I-131
Acute Myeloid Leukemia
Phase 3
0 Comments on ATNM stock
Newest
Trialfinder
betaCompletedLintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
Not yet recruitingVenetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
RecruitingVenetoclax and Lintuzumab-Ac225 in AML Patients
TerminatedA Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Conversation